Communiqués Bayer AG Swiss Exchange

Actions

BAYN

DE000BAY0017

Produits pharmaceutiques

Temps réel estimé Tradegate 08:08:05 01/10/2026			Varia. 5j.	Varia. 1 janv.
47,66 ^EUR	-20,58%		0,00%	-

30/09	Les États de l’Union européenne (UE) opposés à l’autorisation sans limitation de durée des pesticides	DP
30/09	L'inflation revient (encore) au centre du jeu

Communiqués

30/09	Bayer : BlueRock Therapeutics’ investigational cell therapy lemiretprocel (OpCT-001) for primary photoreceptor diseases granted orphan drug designations by FDA and EMA	PU
29/09	MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option	BU
28/09	U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer	BU
17/09	Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs	BU
17/09	Bayer : Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs	PU
17/09	Bayer : U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes	PU
17/09	Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes	BU
10/09	Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road	BU
10/09	U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer	BU
09/09	Bayer : U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer	PU
09/09	Bayer : and Neste close commercial agreement to jointly scale newgold® winter canola for biofuels production	PU
09/09	BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION	BU
09/09	Bayer : initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation	PU
03/09	Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches	AQ
31/08	Bayer : Finerenone slowed kidney function decline and reduced kidney-cardiovascular risk versus placebo in patients with hypertensive nephropathy	PU
30/08	Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026	BU
29/08	Bayer : AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress	PU
24/08	Bayer : sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer	PU
20/08	Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026	BU
17/08	LYNKUET® (élinzanétant) obtient une autorisation de mise en marché élargie au Canada pour le traitement des symptômes vasomoteurs modérés ou graves causés par un traitement endocrinien adjuvant du cancer du sein	BU
13/08	Bayer : Aflibercept 8 mg application for macular edema following retinal vein occlusion accepted for review in China	PU
04/08	Bayer : Q2 Media Update	PU
04/08	Bayer : Second Quarter 2026 Results and Media Update	PU
04/08	Bayer : operationally on track, decisive progress on strategic priorities	PU
30/07	Bayer : submits application for next indication of Kerendia in China	PU